描述医疗器械儿童标签中的不一致性
Grzegorz Zapotoczny1,2, Alexis Snitman3, Payal Shah4
1Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
JAMA network open
|December 4, 2025
概括
美国食品和药物管理局 (FDA) 批准的大多数高风险医疗器械缺乏特定的儿科年龄标签,导致安全和监测问题. 美国食品和药物管理局应实施强制性儿科设备标签要求.
科学领域:
- 医疗器械规则 医疗器械规则
- 儿科安全 儿科安全
- 监管政策 监管政策
背景情况:
- 美国食品和药物管理局 (FDA) 对医疗器械的儿科年龄标签提出了不具约束力的建议,与药品的强制性规定不同.
- 这种缺乏特定的标签有助于非标签的设备使用,影响患者安全,风险分层,临床实践,营销和报销.
- 适当的设备标签对于监管监督和有效的医疗保健服务至关重要.
研究的目的:
- 评估2008年至2017年期间FDA批准的III类医疗器械的儿科年龄标签的变化.
- 为了评估遵守FDA对儿科标签的不具约束力的年龄范围建议.
- 检查设备类型,临床应用,以及将儿科患者纳入临床试验.
主要方法:
- 一项回顾性横截面研究,分析了来自FDA公共数据库和国会报告 (2008-2017) 的数据.
- 两名医生独立审查并为101种独特的设备分配了临床描述符.
- 进行描述性分析和统计比较 (学生t测试) 来评估标签和试验数据.
主要成果:
- 只有25.7%的设备具有特定的年龄范围,50.5%的设备不适用于18岁以下的患者.
- 仅有7.9%的设备遵循FDA推的儿科年龄范围;只有4个使用完全结构化的范围.
- 虽然59.4%的试验包括儿科患者,但只有32.7%包括18岁以下的患者.
结论:
- 2008年至2017年间批准的大多数高风险医疗器械未经评估或未适用于18岁以下的儿童.
- 这种标签差距给临床使用,补偿,研究和政策带来了重大挑战.
- 美国食品和药物管理局应该制定强制性的儿科标签要求设备,考虑到年龄和其他关键因素.
相关概念视频
Drug Dosing: Infants and Children
226
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226
Pharmacokinetics in Pediatric Patients: Drug Excretion
188
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
188
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
219
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
219
Drug Nomenclature
2.9K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
2.9K
Guidelines for Nursing Documentation I
1.7K
Quality documentation and reporting share essential characteristics that ensure they are practical and valuable resources for those who use them. These characteristics are:
Factual:
The following points emphasize the significance of upholding accurate and unbiased documentation in healthcare.
Factual:
The following points emphasize the significance of upholding accurate and unbiased documentation in healthcare.
1.7K
Pharmacokinetics in Pediatric Patients: Drug Distribution
231
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
231


